ADORA2A and glioblastoma: Additionally, the encapsulated A2AR inhibitor can modulate immunosuppressive tumor microenvironment by blocking adenosine‐A2AR pathway, which further boosts the antitumor immunological effect to observably suppress the orthotopic GBM progression.